Elevation of FGF23 levels have been shown to be a surrogate marker of FGFR1 inhibition [22], and in particular, circulating FGF23 levels were increased by Lenvatinib therapy in thyroid cancer [23]. The gene discussed is FGF23; the disease is thyroid gland carcinoma.